
Testosterone treatment can change muscle mass without matching strength gains. Learn how clinical guidance separates body composition from performance.

Myth: more testosterone means more muscle and better performance; clinically, testosterone treatment for diagnosed hypogonadism can increase muscle mass without a matching improvement in strength or physical function.
This article is for informational purposes and is not medical advice. Concerns about symptoms, hormone results or testosterone treatment require an individual assessment by a qualified clinician.
The European Association of Urology (EAU) guideline recognizes a body-composition effect of testosterone therapy in men with diagnosed hypogonadism. Treatment can increase muscle mass and reduce fat mass. Overall body weight may change little despite those shifts.
That distinction matters when reading a study or evaluating a treatment claim. A body-weight result answers a different question from a measurement of muscle or fat mass. Limited weight change does not necessarily mean body composition stayed the same.
The reverse mistake is to treat a favorable body-composition change as proof of better performance. The EAU guideline reports evidence for increased muscle mass alongside mixed or modest findings for strength and walking outcomes. Those findings need to remain separate rather than being combined into a broad claim that treatment improves everything related to muscle.
A useful way to read the evidence is to identify the outcome being discussed:
These are related questions, but they are not interchangeable results. Evidence for the first does not automatically answer the others. A claim about power also needs evidence about power rather than a lean-mass result presented under a different name.
Testostra’s guide to reading muscle and fat changes separately offers further context for understanding body-composition findings without turning them into a performance score.
The EAU guideline cites a meta-analysis of 2,043 patients older than 60 that found no significant improvement in muscle strength with testosterone therapy compared with placebo. That finding challenges the assumption that an increase in muscle mass necessarily produces a measurable strength benefit.
It also supports a clear boundary around treatment claims. In its recommendations, the EAU advises against using testosterone therapy to improve physical strength in ageing men. A discussion of treatment for diagnosed hypogonadism should not be repackaged as a general recommendation for getting stronger.
The wording of the finding matters. “No significant improvement” in that analysis is not the same as proof that no patient could ever experience a strength benefit. It describes the result of the comparison studied rather than a prediction for every individual.
Responsible reporting therefore keeps the strength result attached to the strength question. A body-composition benefit remains a body-composition benefit even when another outcome does not show a clear improvement. Neither result needs to be exaggerated or dismissed to make the evidence sound consistent.
The EAU guideline’s account of the Testosterone Trials provides another example of why outcomes need careful labels. In the dedicated physical-function trial, testosterone treatment did not substantially improve the proportion of men whose six-minute walking distance increased by more than 50 metres. It also did not substantially improve the distance gained within that trial group.
When the broader trial population was considered, the guideline reported a statistically significant but modest effect on those walking outcomes. The dedicated physical-function result and the broader-population result are both part of the evidence. Reporting only the more favorable finding would leave out important context.
The word “modest” should remain attached to that broader finding. Reporting statistical significance without the guideline’s description of the effect would give readers an incomplete picture of its practical meaning.
Walking results also answer a different question from muscle-mass measurements. A change in mass does not itself establish that walking improved. Equally, a walking-test finding should not be stretched into a promise about gym strength or power.
This is the central discipline when reading testosterone research: name the outcome before judging the benefit. “Physical improvement” is too broad when the actual evidence concerns a specific measurement in a particular trial population.
The AAMC describes the Testosterone Trials as involving men aged 65 and older with hypogonadism. It reports mixed findings overall and characterizes the benefits found in carefully conducted trials as modest.
Those participants are not interchangeable with all men in their 30s, 40s or 50s who are concerned about training progress. The older-patient strength analysis also has a defined age group. Neither body of evidence should be presented as a universal account of how every adult man will respond.
The AAMC quotes researcher Shalender Bhasin describing physical-performance effects in elderly people as “modest.” It also says that whether those effects translate into clinical benefits for frail people or those with mobility disabilities remains to be established in larger randomized trials.
The practical implication is to keep the population visible whenever a result is discussed. A claim should identify whether it concerns older men with hypogonadism or a different group. A clinical question about mobility should also remain distinct from a general interest in gaining muscle.
The treatment findings above concern diagnosed hypogonadism. They do not make testosterone therapy a general-purpose gym intervention. The EAU guideline advises against its use in eugonadal men, meaning men with normal testosterone levels.
That distinction prevents a common leap in reasoning: moving from “treatment can increase muscle mass in hypogonadism” to “more testosterone should improve any man’s training results.” The second statement does not follow from the first. It changes both the clinical population and the claim being made.
For someone concerned about possible low testosterone, a laboratory result belongs alongside symptoms and a clinician’s evaluation. Gym progress is not a stand-alone hormone test. The evidence discussed here does not establish a method for diagnosing hypogonadism from training response.
Testostra’s explanation of what a clinical assessment involves provides context for that medical discussion. It is a separate task from deciding whether a workout or body-composition goal has been reached.
A testosterone measurement and a performance assessment answer different questions. The treatment evidence described here does not provide a formula for converting a personal hormone result into an expected amount of muscle gain from resistance training.
This does not mean testosterone is irrelevant to muscle. The EAU’s body-composition findings show why that would be the wrong conclusion. It means that evidence of a treatment effect in a defined clinical setting should not be turned into an individual training forecast.
Questions about total testosterone, free testosterone and SHBG belong within the interpretation of a hormone report. Readers seeking that background can consult Testostra’s guide to putting hormone measurements in context. Understanding the report is different from using it as a score for future gym performance.
A responsible reading of a muscle-related testosterone claim starts with a few questions:
These questions help separate a supported finding from an expanded promise. They also make a clinical conversation more precise: the issue can be muscle mass, strength or everyday function rather than an undefined expectation that a higher hormone number should improve all three.
Evaluate testosterone claims by matching the measured outcome to the population studied, and leave personal diagnosis or treatment decisions to qualified care rather than treating lean mass or a hormone number as a performance forecast.
Muscle outcomes and hormone measurements answer different questions, and Testostra addresses that distinction through evidence-led education rather than personal performance predictions. Readers sorting through total testosterone, free testosterone and SHBG can use its reporting to understand biomarkers in context and separate clinical findings from marketing claims without receiving an individual diagnosis or hormone protocol.
Testostra follows testosterone research, clinical guidance and emerging evidence without turning general information into personal treatment advice.




Send us a question, research idea or topic suggestion. Reader questions help shape future Testostra content.
Contact Testostra